Evidence map›Paper›PMID 30368626›Full record

ArticleInvestigational new drugs2019

A novel humanized anti-PD-1 monoclonal antibody potentiates therapy in oral squamous cell carcinoma.

Y Cai, Fei Wang, Q Liu, Z Li, D Li, Z Sun

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trends in immunotherapy for oral squamous cell carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2025
    Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Y CaiDepartment of Stomatology, Renji Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, 200127, China.
Fei WangDepartment of Neurosurgery, Shanghai Tongji Hospital, Tongji University, School of Medicine, Shanghai, 200065, China.
Q LiuDepartment of Clinical Laboratory, Baoshan Traditional Chinese and Western Medicine Hospital, Shanghai, 201900, China.
Z LiPutuo District Mental Health Center, Shanghai, 200065, China.
D LiDepartment of Clinical Laboratory, Shanghai Tongji Hospital, Tongji University, School of Medicine, Shanghai, 200065, China. lidong@tongji.edu.cn.
Z SunDepartment of Clinical Laboratory, Shanghai Tongji Hospital, Tongji University, School of Medicine, Shanghai, 200065, China. sunzujun1976@126.com.
Tongji Hospital · CNCentral Hospital of Putuo District · CNRenji Hospital · CNShanghai Traditional Chinese Medicine Hospital · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, immune checkpoint inhibitors have been shown to extend the survival of many cancer patients. However, few studies have focused on immune checkpoint inhibition for the treatment of patients with oral squamous cell carcinoma (OSCC). Here, by screening at an early stage, we obtained a strain of anti-PD-1 monoclonal antibody (mAb) that targets programmed cell death-1 (PD-1) does not contain the C

Indexed as

AnimalsAntibodies, Monoclonal, HumanizedApoptosisCarcinoma, Squamous CellCell ProliferationFemaleHumansMaleMiceMice, Inbred NODMice, SCIDMouth NeoplasmsPrognosisProgrammed Cell Death 1 ReceptorTumor Cells, CulturedXenograft Model Antitumor AssaysAntibodies, Monoclonal, HumanizedPDCD1 protein, humanProgrammed Cell Death 1 ReceptorMonoclonal antibodyOral squamous cell carcinomasPD-1PD-L1

Identifiers

PMID30368626
OpenAlexW2898374602

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.